Physician profile
Boris Vatel
NPI 1992783526
$3,353.46
in general payments reported to CMS, 2019-2025
25 companies · $82.03 in 2025
The $82.03 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.48 · 2021: $46.92 · 2022: $2,485 · 2023: $258 · 2024: $465 · 2025: $82.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $510.14 | 2022-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $401.59 | 2022 | |
| Corium, LLC | $274.33 | 2022-2023 | Azstarys |
| Abbvie INC. | $261.26 | 2022-2024 | |
| Alkermes, INC. | $217.05 | 2022-2024 | Lybalvi |
| Axsome Therapeutics, INC. | $194.20 | 2022-2024 | Auvelity |
| Bausch Health US, LLC | $164.41 | 2022 | |
| Vanda Pharmaceuticals INC. | $162.05 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.18 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $134.61 | 2022 | |
| Ironshore Pharmaceuticals INC. | $121.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $119.57 | 2022 | |
| Sunovion Pharmaceuticals INC. | $96.21 | 2022 | |
| Indivior INC. | $87.35 | 2021-2022 | |
| Tris Pharma INC | $76.32 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $67.02 | 2024 | |
| Neurocrine Biosciences, INC. | $64.05 | 2022 | |
| Lundbeck LLC | $63.57 | 2022 | |
| Supernus Pharmaceuticals, INC. | $56.27 | 2022 | |
| Harmony Biosciences LLC | $36.13 | 2022 | |
| Merck Sharp & Dohme LLC | $25.04 | 2022 | |
| Neos Therapeutics, LP | $23.36 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.48 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.22 | 2022 | |
| Almatica Pharma LLC | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Vatel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.